In many cultures, the image "Same water, different flow" describes the idea that two rivers can flow differently in the same bed. This concept applies to the brains of women, men, and gender-diverse people: not better or worse, but different in patterns—and these differences are context-dependent, malleable, and clinically relevant. The myth of the "male" or "female" brain falls short. The exciting truth is that biology and socioculture intertwine—and those who understand this make smarter health and performance decisions.

Gender is multilayered. Sexbiological characteristics such as chromosomes, hormones, gonads and Gendersocial roles, expectations, and identities overlap and shape behavior, stress responses, and health risks. In the brain, researchers rarely speak of strict dichotomies but rather of mosaicsindividual mixtures of traits, some of which occur more frequently in one gender but overlap. Therefore, group differences may exist even as individuals break the "pattern." Important for high performers: both levels—biology and context—affect cognition, recovery, medication effects, and disease risks. Those who align their health management accordingly minimize misdecisions and gain performance reserves and longevity.

Misunderstandings cost health. Stereotyping cognitive abilities ("men are better spatially, women verbatim") can distort decisions in education, career, and self-image—and thereby misdirect training, motivation, and stress biology. A recent study involving cis women, cis men, and trans/non-binary individuals showed that cognitive profiles vary, are not rigidly sexually dimorphic, and explicit stereotypes showed no consistent performance effect; differences varied depending on test conditions ^[1]. Clinically significant is the ignorance of biological differences in therapies: in oncology, the efficacy and side effects of immunotherapy, chemotherapy, targeted therapy, and radiation therapy vary between the sexes; sex should be integrated into personalized treatment, otherwise suboptimal decisions and toxicities threaten ^[2]. For brain health, it has become evident that sex/gender differences in glial activity and biomarkers could differently shape the course of neurodegenerative diseases like Alzheimer's—with implications for prevention, diagnostics, and timing of interventions ^[3][4].

In an experimental study with 488 adults (cis women, cis men, trans/non-binary), participants completed eight cognitive tasks and received either stereotypical hints or none depending on the group. The result: gender-diverse individuals exhibited a distinct pattern—similar to cis men in spatial orientation, similar to cis women in fine motor skills, and superior in verbal learning. Explicit stereotypes did not directly influence performance; rather, differences varied according to the test protocol, explaining the inconsistent literature on "sexually dimorphic cognition" and emphasizing the role of context and design ^[1]. In precision neurology, sex/gender-specific biomarkers are coming into focus. A review reports that peripheral microRNAs—especially miR-206—exhibit sex-specific signatures in neurodegenerative diseases. If sex is ignored in assessment, bias arises; the authors advocate for patient stratification to sharpen diagnosis, prognosis, and treatment ^[4]. Complementarily, a cohort analysis of cognitively unimpaired but Alzheimer-risk older adults indicated that CSF markers of glial reactivity (sTREM2, YKL40, GFAP) affect their relationship to amyloid, tau, and hippocampal volume differently depending on sex/gender: women showed higher amyloid and p-tau loads with increasing glial markers, while men exhibited a stronger coupling of YKL40 to hippocampal atrophy with greater tau load. This indicates sex/gender-specific pathways in AD progression and motivates temporally differentiated prevention windows ^[3]. Beyond the brain, a translationally focused oncology review underscores that the effectiveness and toxicity of common cancer therapies differ between biological sexes—an argument for consistently integrating sex as a variable into personalized decisions and expanding research programs to incorporate gender aspects ^[2].

- Build your prevention profile according to sex/gender: Discuss familial risks for neurodegenerative diseases with your doctor and, when available and clinically meaningful, have biomarkers such as CSF glial markers (YKL40, sTREM2, GFAP) interpreted in the context of sex/gender. Studies indicate different associations with amyloid, tau, and neurodegeneration ^[3].
- Think "stratification": When participating in studies or tracking your data with health tech tools, specify sex and gender. This supports the development of gender-specific biomarkers (e.g., miRNAs like miR-206) for more precise early diagnosis and treatment guidance ^[4].
- Avoid cognitive stereotypes in daily life: Actively train areas you need—spatial navigation, verbal learning, fine motor skills—independently of gender clichés. Research shows varying, context-dependent differences instead of hard dichotomies ^[1].
- Personalize medications and recovery: Actively inquire about sex-specific evidence concerning dosage, efficacy, and side effects—especially in oncology, immunotherapy, or targeted therapies. This improves benefit-risk profiles and reduces toxicities ^[2].
- Support research: Donate or get involved in projects that identify sex/gender-specific biomarkers in neurological diseases. This accelerates prevention and tailored treatment—your contribution today can open future treatment windows ^[4][3].

Those who aim for high performance need precision: Replace myths with measurable data and include sex and gender in prevention, training, and therapy. Support research into gender-specific biomarkers and demand personalized decisions. This way, you protect your brain—and unlock reserves for energy, focus, and longevity.